Image Credits: Canva
Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.
The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.
Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.
Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:
Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.
Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.
Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.
One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.
Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:
"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."
Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.
The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.
Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.
One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.
Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:
"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."
He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.
With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.
As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.
Credit: Health Ministry
India has created more than 880 million digital health identities under the country’s flagship mission, the Ayushman Bharat Digital Mission, said Union Health Minister JP Nadda today while addressing the 79th World Health Assembly (WHA) in Geneva.
Speaking at the plenary session, Nadda reaffirmed the country’s commitment to universal health coverage, digital health innovation, and global health solidarity.
“Ayushman Bharat Digital Mission is strengthening India’s national digital health ecosystem by creating over 880 million unique digital health identities, which facilitate longitudinal health records and a seamless continuum of care,” he said.
He noted that India is accelerating towards universal health coverage by expanding access to quality and affordable healthcare with a “whole-of-government” and “whole-of-society” approach.
The Union Health Minister informed the Assembly that India has established over 1,85,000 Ayushman Arogya Mandirs across the country to provide comprehensive primary healthcare services closer to communities.
The Minister also underlined the scale and impact of Ayushman Bharat Pradhan Mantri Jan Arogya Yojana, the world’s largest public health assurance scheme, covering nearly 600 million beneficiaries, particularly the most vulnerable sections of society.
Also read: 15 Lakh Indian Chemists To Join May 20 Strike; Govt Says Jan Aushadhi, AMRIT Stores To Stay Open
Further, Nadda emphasized India’s efforts towards pandemic preparedness and resilient public health systems. He stated that the government is continuously strengthening healthcare infrastructure and emergency response capacities to effectively address future public health challenges.
He also highlighted the transformative role of technology in healthcare and stressed the growing role of Artificial Intelligence in healthcare in the country.
The Minister informed delegates that India has recently launched the Strategy for Artificial Intelligence in Healthcare for India. He emphasized that “the future of AI depends on our collective ability to build ethical and human-centric systems.”
Nadda reaffirmed India’s role as the “Pharmacy of the World” by highlighting the country’s leadership in the production of affordable generic medicines and vaccines.
Recalling India’s contribution during the COVID-19 pandemic, he stated that under the Vaccine Maitri initiative, India supplied nearly 300 million vaccine doses to around 100 countries, reflecting the nation’s enduring commitment to global health cooperation and solidarity.
Read More: No Ebola Case in India, Public Risk Low: Govt Steps Up Surveillance at Airports and Seaports
The 79th WHA will be held from May 18 to May 23 in Geneva under the theme “Reshaping global health: a shared responsibility.”
In his opening remarks at the Assembly, the WHO chief Tedros Adhanom Ghebreyesus referred to recent outbreaks of hantavirus and Ebola, as well as challenges including economic crises and climate change, stressing the need to “build a new global health architecture fit for the future.”
Tedros said this year’s Assembly will consider a proposal for a member state-led, WHO-hosted joint process to reform the global health architecture, Xinhua News Agency reported.
The 79th WHA will review over 60 agenda items, including technical issues such as noncommunicable diseases, mental health, universal health coverage, primary health care, and prevention and response to public health emergencies, as well as administrative issues such as financing, implementation, auditing, and oversight of the WHO’s 2026–2027 programme budget.
As the WHO’s highest decision-making body, the annual WHA is usually held in May in Geneva. Its main functions include deciding WHO policies and reviewing and approving the budget program. This year’s Assembly is scheduled to conclude on .
Credit: iStock
The third recorded outbreak of the rare Bundibugyo strain of Ebola in the Democratic Republic of Congo (DRC) has been declared a Public Health Emergency of International Concern (PHEIC) by the World Health Organization (WHO).
The 17th outbreak of Ebola virus in the Democratic Republic of the Congo has claimed over 130 lives, with more than 513 suspected cases, BBC quoted local officials as saying.
As per the US Centers for Disease Control and Prevention (CDC), there are also two confirmed cases and one death in Uganda.
With the disease spreading to newer regions and both the death toll and case count rising, experts have raised fresh global health concerns, noting that delayed detection may have allowed the virus to spread across multiple regions.
According to health authorities, early tests failed to identify the correct Ebola strain, leading to crucial weeks being lost before containment efforts began.
The first known case was reportedly a healthcare worker in Bunia, DRC, who began experiencing fever, hemorrhaging, vomiting, and intense malaise on April 24. That person later died, according to the WHO.
However, it took another three weeks before health officials officially confirmed that Ebola was spreading.
Also read: Ebola Outbreak: University of Glasgow Researcher Explains Why Bundibugyo Virus Is Concerning
The WHO noted that a critical four-week detection gap between the onset of symptoms in the presumed index case, and the laboratory confirmation of the outbreak on May 14, suggests a low clinical index of suspicion among healthcare providers.
“This is compounded by the presence of co-circulating arboviruses and influenza-like illnesses, masking the initial index of suspicion for Ebola disease and exacerbating community transmission,” the WHO said.
Further, the infection and death of four healthcare workers within four days at Mongbwalu General Referral Hospital underscores critical breaches in infection prevention and control (IPC) protocols. A large number of community deaths have also been reported, potentially associated with unsafe burial practices, the WHO added.
The US CDC stated that the initial samples tested in DRC were negative for the Ebola virus, but by May 15, eight out of 13 samples tested positive, while five were inconclusive.
Using genetic fingerprinting, the illnesses were identified as the Bundibugyo virus, one of the four types of orthoebolaviruses that cause Ebola disease in people.
On May 17, the WHO declared the Ebola outbreak in Central Africa a “public health emergency of international concern.”
This marks the 17th Ebola outbreak in DRC since 1976. The previous outbreak ended in December 2025.
The current outbreak is the third involving the Bundibugyo virus. The strain was first identified during an outbreak in Uganda in 2007, which resulted in 131 cases and 42 deaths.
Another Bundibugyo outbreak was reported in 2012, killing 50 per cent of infected people in Uganda and 34 per cent in DR Congo.
Speaking exclusively to HealthandMe, Professor Emma Thomson, Director of the Centre for Virus Research (Virology) in the School of Infection and Immunity at University of Glasgow, said the initial negative GeneXpert Ebola tests suggest the outbreak may have gone undetected for some time.
“The reports that initial GeneXpert Ebola testing was negative suggest that the outbreak may have gone undetected for some time, with early diagnostic blind spots delaying recognition,” she said.
Notably, Ebola cases have also been identified in Kinshasa and Kampala. According to Professor Emma, the spread to locations “hundreds of kilometers from Ituri province” indicates that the virus had already moved through human mobility networks before full containment measures were in place.
As a result, “the number of cases is going to go up pretty dramatically,” public health expert and Ebola survivor Craig Spencer told Associated Press.
Health experts stated that the outbreak went undetected for weeks because early tests looked for the wrong strain of the virus.
“Because early tests looked for the wrong strain of Ebola, we got false negatives and lost weeks of response time,” Matthew M Kavanagh of Georgetown University told AP. “We are playing catch-up against a very dangerous pathogen.”
More concerning is the fact that the outbreak is caused by the Bundibugyo strain, a rare form of Ebola for which there are no approved vaccines or specific treatments.
“We do not currently have a proven, licensed, Bundibugyo-virus-specific vaccine available for outbreak control,” Professor Emma told HealthandMe, stressing the need for urgent vaccine research.
She also highlighted the importance of strengthening therapeutics against the Ebola virus.
Credit: AIIMS/X
Amid an India-wide strike of more than 15 lakh chemists and druggists slated for May 20, the government today noted that access to medicines will remain unaffected in the country.
“All pharmacy chains and hospital pharmacy stores, Jan Aushadhi stores, AMRIT Pharmacy stores will remain open tomorrow,” according to official sources from the Ministry of Health.
These stores will remain open “in addition to the many state and chemist associations who have already pulled out from the strike,” the sources said.
Retail pharmacy associations from at least 12 states and Union Territories, including West Bengal, Kerala, Maharashtra, Punjab, Karnataka and Uttar Pradesh, have formally distanced themselves from the strike call, citing “public interest”.
Earlier this week, the All India Organisation of Chemists and Druggists (AIOCD) announced that more than 15 lakh chemists and druggists across the country will keep their medical stores shut on May 20 to protest against illegal online sale of medicines and “unprofessional competition” by corporate firms.
The trade body flagged the sale of prescription drugs without proper verification and warned that AI-generated fake prescriptions may worsen the misuse of antibiotics.
The nationwide strike also demands the withdrawal of notifications issued during the COVID-19 pandemic that allegedly enabled the misuse of online medicine sales, said AIOCD president and former MLC Jagannath Shinde during a press conference in Mumbai.
Shinde noted that online sales had led to the circulation of fake drugs, antibiotics, and scheduled medicines without prescriptions, posing a serious threat to public health, particularly among the youth.
Also read: ‘I Was Vocal About Cancer But Silent About Menopause Out Of Shame’, Says Actress Lisa Ray
“The online sale of drugs has become hazardous for the nation and needs to be checked on priority. Moreover, deep discounts offered by online companies were proving to be a death knell for small chemists and retailers,” he alleged.
During the COVID pandemic, the government had issued special exemptions to ensure home delivery of medicines. Shinde pointed out that those provisions are continuing even after the pandemic ended.
Online companies were exploiting these relaxations and engaging in unfair competition through discounts ranging from 20 to 50 per cent, he added.
Read More: No Ebola Case in India, Public Risk Low: Govt Steps Up Surveillance at Airports and Seaports
Official sources in the Central Drugs Standard Control Organisation (CDSCO) reiterated that public health and patient access to medicines remain paramount.
They noted that any disruption in the functioning of chemist shops has the potential to cause serious inconvenience to patients, particularly vulnerable groups dependent on regular access to life-saving and essential medicines, besides impacting critical medical supply chains.
“Any disruption in the functioning of chemist shops has the potential to cause serious inconvenience to patients and impact critical medical supply chains,” a source said.
They also added that constructive dialogue remains the preferred mechanism for addressing sectoral concerns while ensuring uninterrupted healthcare services for citizens across the country.
© 2024 Bennett, Coleman & Company Limited